Myriad Genetics, Inc. (MYGN)

Over the past six months, Myriad Genetics' stock price has declined, with a 38.68% decrease as of April 7, 2026. Key events impacting the stock include Q2 2025 financial results with a GAAP net loss due to non-cash impairment charges, Q3 2025 financial results with a strategic collaboration with SOPHiA GENETICS, Q4 2025 earnings beating estimates, FDA approval for the MyChoice CDx Test, a consensus "hold" rating from analysts, and a downtrend indication from technical analysis.

There is no specific price data available for a detailed seasonality analysis of Myriad Genetics' stock or products. Therefore, it is not possible to provide a comprehensive summary of demand seasonality for Myriad Genetics, Inc. products and services at this time.

Myriad Genetics, Inc. is an American genetic testing and precision medicine company founded in 1991 and headquartered in Salt Lake City, Utah. The company develops and markets molecular diagnostic tests that provide insights into the genetic basis of human diseases, helping assess disease risk, predict drug response, and evaluate disease progression. Myriad's products and services include hereditary cancer tests like MyRisk Hereditary Cancer and BRACAnalysis, tumor profiling tests like Prolaris and MyChoice CDx, prenatal tests like Foresight and Prequel, and pharmacogenomics tests like GeneSight.

Myriad Genetics is headquartered in Salt Lake City, Utah, and operates in the U.S. and internationally. Myriad International is listed as a subsidiary. The company's stock is traded on the NASDAQ (MYGN) and several European exchanges, indicating its global reach.

Myriad Genetics has positioned itself as a leader in molecular diagnostic testing and precision medicine, emphasizing its commitment to the Cancer Care Continuum and focusing on quality, service, and accessibility across its product portfolio. The FDA approval of the MyChoice CDx test is a positive development. However, UnitedHealthcare's changed coverage for multi-gene pharmacogenetic tests and significant non-cash impairment charges have presented challenges.

Myriad Genetics has a mixed ownership structure, with approximately 57.97% of the company's stock owned by institutional investors, 6.53% by insiders, and 35.50% by public companies and individual investors. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Millennium Management Llc.